You are here: Industry Insights > TREMFYA

News List

Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data pharmatimes
October 19, 2020
Janssen has announced new open-label extension data for Tremfya, with the treatment continuing to show high rates of skin clearance through nearly five years in moderate to severe plaque psoriasis.
Tremfya Approved by FDA as Selective Interleukin (IL)-23 Inhibitor for Psoriatic Arthritis americanpharmaceuticalreview
July 22, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by ...
Janssen's Tremfya wins psoriatic arthritis approval pharmatimes
July 16, 2020
Janssen's Tremfya (guselkumab) has been approved in the US as the first selective interleukin (IL)-23 inhibitor for adults with active psoriatic arthritis (PsA).
Janssen’s TREMFYA delivers improvement in psoriatic arthritis joint and skin symptoms at week 52 in phase 3 trials pharmaceutical-business-review
June 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2.
Janssen Submits TREMFYA Application to FDA for Psoriatic Arthritis americanpharmaceuticalreview
September 18, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking ...
Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials pharmaceutical-technology
June 19, 2019
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults with moderate to severe psoriatic arthritis.
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod fiercepharma
March 03, 2019
Johnson & Johnson’s Tremfya put a key rival on defense late last year with head-to-head data, and it’s keeping the heat on its competitors.
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasis pharmaphorum
December 14, 2018
A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.
Janssen’s Tremfya shows superiority in plaque psoriasis to Novartis’ drug at 48 weeks pharmaceutical-technology
December 14, 2018
Johnson & Johnson subsidiary Janssen has announced results from its phase III Eclipse trial comparing its Tremfya (guselkumab) with Novartis’ Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis.....
Plaque psoriasis study claims Tremfya superior to Cosentyx pharmatimes
December 13, 2018
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis' Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.

Previous page 1 2 3 Next page